Cocrystal Pharma, Inc. (COCP) - Dilution Analysis

10-Q filing | 13.8M shares outstanding

S-3 filing: This S-3 filing by Cocrystal Pharma, Inc. details a shelf registration for the issuance and sale of common stock, preferred stock, warrants, and units, with a total offering price of $150,000,000.

10-K filing | 13.8M shares outstanding

10-Q filing | 13.8M shares outstanding

8-K filing: Cocrystal Pharma, Inc. sold 739,426 units, each consisting of one share of common stock and one warrant, to four accredited investors at $1.39 per unit, resulting in gross proceeds of $1.03 million. ($1.03M proceeds)

S-1 filing: This prospectus relates to the resale of up to 5,736,773 shares of our common stock issuable upon exercise of outstanding warrants.

8-K filing: Cocrystal Pharma, Inc. closed a registered direct offering and concurrent private placement on September 15, 2025, issuing 2,764,710 shares of common stock at $1.70 per share, raising gross proceeds of approximately $4.75 million. ($4.75M proceeds)

10-Q filing | 10.2M shares outstanding

10-Q filing | 10.2M shares outstanding

10-K filing | 10.2M shares outstanding

10-Q filing | 10.2M shares outstanding

10-Q filing | 10.2M shares outstanding

10-Q filing | 10.2M shares outstanding

10-K filing | 9.7M shares outstanding

10-Q filing | 10.2M shares outstanding

10-Q filing | 10.1M shares outstanding

8-K filing: Cocrystal Pharma, Inc. filed a prospectus supplement for the offering of up to $7,250,000 shares of common stock pursuant to the At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC.

S-3/A filing: Cocrystal Pharma, Inc. intends to offer and sell securities, including common stock and preferred stock, with a total offering price not exceeding $150,000,000, as described in the prospectus.

10-Q filing | 10.2M shares outstanding

S-3 filing: Cocrystal Pharma intends to offer and sell common stock and preferred stock, with a total offering price not exceeding $150,000,000.

8-K filing: Cocrystal Pharma, Inc. sold 2,030,458 shares of common stock at $1.97 per share to two accredited investors, Fred Hassan and Frost Gamma Investments Trust, for a total purchase price of $4,000,000. ($4.0M proceeds)

10-K filing | 8.1M shares outstanding

10-Q filing | 8.1M shares outstanding

8-K filing: Stock split one-for-12 | Outstanding: 97,469,000 → 8,122,416

10-Q filing | 97.5M shares outstanding

10-Q filing | 97.5M shares outstanding

10-K filing | 97.5M shares outstanding

10-Q filing | 97.5M shares outstanding

10-Q filing | 97.5M shares outstanding

10-Q filing | 71.2M shares outstanding

8-K filing: Cocrystal Pharma, Inc. entered into an Underwriting Agreement with H.C. Wainwright & Co., LLC, to issue and sell 26,000,000 shares of common stock at a public offering price of $1.54 per share, with expected net proceeds of approximately $36.4 million. ($40.04M proceeds)

10-K filing | 35.2M shares outstanding

10-Q filing | 35.2M shares outstanding

8-K filing: Cocrystal Pharma, Inc. entered into an Underwriting Agreement with H.C. Wainwright & Co., LLC to issue and sell 14,285,715 shares of common stock at $1.05 per share, with an option for the underwriter to purchase an additional 2,142,857 shares. ($15.0M proceeds)

10-Q filing | 35.2M shares outstanding

10-Q filing | 35.2M shares outstanding

S-3/A filing: Cocrystal Pharma, Inc. intends to offer and sell common stock and preferred stock, with the total offering price not to exceed $150,000,000.

S-3 filing: Cocrystal Pharma, Inc. intends to offer and sell common stock and preferred stock with a total offering price not exceeding $150,000,000.

10-K filing | 29.9M shares outstanding

8-K filing: Cocrystal Pharma, Inc. entered into a securities purchase agreement for a registered direct offering of 5,037,038 shares of common stock at $1.35 per share, resulting in gross proceeds of approximately $6.8 million, and also settled a lawsuit with Aegis Capital Corporation. ($6.8M proceeds)

8-K filing: Cocrystal Pharma, Inc. sold 8,461,540 shares of common stock at $1.30 per share in a registered direct offering, resulting in gross proceeds of approximately $11.0 million. ($11.0M proceeds)

8-K filing: Cocrystal Pharma, Inc. entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners for a registered offering of 3,492,063 shares of common stock at $0.63 per share, expecting to receive approximately $2.0 million in net proceeds. ($2.2M proceeds)